

Special Authorization Request Form, for:

COSENTYX (*secukinumab*)

The purpose of this form is to obtain medical information required to assess your request for a drug on the Special Authorization (SA) list of the Reformulary. Please ensure that all information, including contact information, is complete. Completing this form is not a guarantee of approval.

PART 1: COMPLETE THIS INFORMATION

Information about plan member

First name: _____ Last name: _____

Group number: _____ Certificate number: _____

Date of birth (DD/MM/YY): _____ Gender: _____

Address: _____

City/Town: _____ Province: _____ Postal code: _____

Email: _____ Phone: _____

COORDINATION OF BENEFITS

Coverage through another health benefit plan or provincial plan

Do you or your dependents have drug coverage through another health benefits, insurance company or provincial plan? Yes No

If yes, provide the following: Name of plan member: _____

Policy/Plan number: _____ Certificate number: _____

Patient assistance program

Have you enrolled in a patient assistance program? Yes No

If yes, provide your patient assistance program ID number: _____

Provide the patient assistance program:

Contact name: _____ Phone: _____

PART 2: TO BE COMPLETED BY YOUR DOCTOR (PHYSICIAN)

Physician Information

First name: _____ Last name: _____

License: _____ Phone: _____

Address: _____

City/Town: _____ Province: _____ Postal code: _____

Physician's signature: _____

(confirming the below information to be correct)

Drug being requested through Special Authorization

New request Request for continuation of therapy

DIN: _____ Product name: _____

Strength: _____ Dosage: _____

Site of Administration

- Home Private clinic Hospital
 Doctor's office Cancer centre LTC facility

CLINICAL INFORMATION

Diagnosis

- Ankylosing Spondylitis (AS)
- Plaque Psoriasis
- Plaque Psoriasis (adolescent patients)
- Psoriatic Arthritis
- Non-Radiographic Axial Spondyloarthritis

Physician specialty

- Dermatologist
- Pediatrician
- Rheumatologist

CLINICAL INFORMATION (cont.)

Criteria for initial coverage, confirm the following:

FOR ANKYLOSING SPONDYLITIS (AS)

- Patient is 18 years of age or older; and
- Patient must be diagnosed with moderate to severe Ankylosing Spondylitis*; and
- Patient is intolerant to, or has tried and failed to respond to adequate trials of biosimilars of *infliximab*, *etanercept*, or *adalimumab*, or CIMZIA (*certolizumab pegol*), or BIMZELX (*bimekizumab*)

*Ankylosing Spondylitis is defined by at least two of the following clinical criteria

- Low back pain and stiffness for > 3 months that improves with exercise but is not relieved by rest; or
- Limitation of motion of the lumbar spine in both the sagittal and frontal planes; or
- Limitation of chest expansion relative to normal values correlated for age and sex

NOTE: Duration of initial approval is 1 year

FOR PLAQUE PSORIASIS

- Patient is 18 years of age or older; and
- Patient diagnosed with severe Plaque Psoriasis (PASI score ≥ 12 and BSA involvement $\geq 10\%$); and
- Patient is intolerant to, or has tried and failed to respond to adequate trials of biosimilars of *infliximab*, *etanercept*, *adalimumab*, or *ustekinumab*, or CIMZIA (*certolizumab pegol*), or BIMZELX (*bimekizumab*); and
- Patient has failed to respond to, is intolerant to, or unable to access at least a 12-week trial of phototherapy

NOTE: Duration of initial approval is 12 weeks

Important note: Patient should be monitored to determine if continuation of therapy beyond 12 weeks is required. Patient not responding adequately at 12 weeks should have treatment discontinued.

FOR PLAQUE PSORIASIS (adolescent patients)

- Patient is between 12 - 17 years of age; and
- Patient must be diagnosed with severe Plaque Psoriasis (PASI score ≥ 12 and BSA involvement $\geq 10\%$); and
- Patient is intolerant to, has contraindications to, or has inadequate response to either *methotrexate* or *acitretin* for at least a 6-month trial; and
- Patient has failed to respond to, is intolerant to, or unable to access at least a 12-week trial of phototherapy

NOTE: Duration of initial approval is 12 weeks

Important note: Patient should be monitored to determine if continuation of therapy beyond 12 weeks is required. Patient not responding adequately at 12 weeks should have treatment discontinued.

FOR PSORIATIC ARTHRITIS

- Patient is 18 years of age or older; and
- Patient must be diagnosed with Psoriatic Arthritis; and
- Patient is intolerant to, or has tried and failed to respond to adequate trials of biosimilars of *infliximab*, *etanercept*, *adalimumab*, *ustekinumab*, or CIMZIA (*certolizumab pegol*), or BIMZELX (*bimekizumab*).

NOTE: Duration of initial approval is 1 year

FOR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS

- Patient is 18 years of age or older; and
- Patient diagnosed with severe active non-radiographic axial spondyloarthritis; and
- Patient has objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence; and
- Patient has had an inadequate response to, has had a serious adverse reaction or has a contraindication to nonsteroidal anti-inflammatory drugs; and
- For patients with concurrent peripheral spondyloarthritis: patient has had an inadequate response to, or is intolerant or has contraindication to a DMARD (e.g., *sulfasalazine*, *methotrexate*, *leflunomide*); and
- Maintenance dose of secukinumab should be 150 mg subcutaneously once monthly

NOTE: Duration of initial approval is 1 year

Request for continuation of therapy, confirm the following:

FOR ANKYLOSING SPONDYLITIS

- Patient demonstrates a positive response to therapy defined by a 50% relative change or absolute change of 2 (scale 0-10) in BASDAI score from baseline; or
- Patient has documented significant functional improvement from the ongoing therapy with biologic (e.g. measured by outcomes such as HAQ or “ability to return to work”)

NOTE: Duration of continued approval is 1 year

FOR PLAQUE PSORIASIS

- Patient demonstrates continued therapeutic benefit, outweighing any potential risks. Specifically, after 3 months of therapy patients who respond to therapy should have:
 - at least a 50% reduction in PASI; and
 - at least a 50% reduction in BSA involvement; and
 - at least a 5 point reduction in DLQI score

NOTE: Duration of continued approval is 1 year

FOR PLAQUE PSORIASIS (adolescent patients)

- Patient demonstrates continued therapeutic benefit, outweighing any potential risks. Specifically, after 3 months of therapy patients who respond to therapy should have:
 - at least a 50% reduction in PASI; and
 - at least a 5 point reduction in CDLQI (Children’s Dermatology Life Quality Index) score

NOTE: Duration of continued approval is 1 year

FOR PSORIATIC ARTHRITIS

- Patient demonstrates continued therapeutic benefit, such as a 20% reduction in swollen joint count and a minimum improvement in 2 swollen joints over the previous year

NOTE: Duration of continued approval is 1 year

FOR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS

- Patient demonstrates a positive response to therapy defined by a 50% relative change or absolute change of 2 (scale 0-10) in BASDAI score from baseline; or
- Patient has documented significant functional improvement from the ongoing therapy with biologic (e.g., measured by outcomes such as HAQ or “ability to return to work”)

NOTE: Duration of continued approval is 1 year

SPECIAL NOTES

Describe any intolerances to therapy: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information that the physician believes is important to this review? _____

Update: September 2024